bupropion for PMDD
A single patient reports that bupropion (Wellbutrin) substantially helped their PMDD symptoms.
Hypothesized mechanism
Bupropion's norepinephrine-dopamine reuptake inhibition may improve PMDD-related mood symptoms.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 5 of 10 overall, a emerging reading, from a community rated emerging in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population). (band F1, ×1.00).
Corroboration
Independence (patient accounts): 0 distinct account(s) across 2 thread(s) (author handles unavailable — counting distinct posts).
Rigor
The report is vague: it provides no dose, timing, duration, or specific symptom changes. Statements like 'holy grail' and 'helped my PMDD' lack the specificity needed for higher scoring.
Specificity
Both the drug (Wellbutrin/bupropion) and the outcome (PMDD improvement) are clearly named and explicitly linked in claim 2 ('Wellbutrin helped my PMDD').
Plausibility
Bupropion is a norepinephrine-dopamine reuptake inhibitor used for depression; its benefit in PMDD is biologically plausible for mood symptoms but is not an established first-line PMDD treatment (SSRIs are). The reported benefit is consistent with general antidepressant action on mood.
Consistency
The two claims agree with each other (both positive), but they likely derive from the same single account, so internal agreement is trivial. No dose/timing details exist to assess coherence.
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Community reports. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Wellbutrin (bupropion) is my holy grail Community report · Reddit ↗
- 2Wellbutrin helped my PMDD Community report · Reddit ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →